Previous 10 | Next 10 |
As the coronavirus pandemic has progressed, healthcare companies engaged in the development and manufacturing of COVID-19 vaccines and therapeutics have become the darlings of the stock market. Shares of most of these companies have increased exponentially in 2020, with much of the gain...
When most of us think of coronavirus stocks, we think of vaccine makers or drug treatment companies. A heart-pump specialist doesn't first come to mind. That's why this company wasn't among the most talked about as the coronavirus treatment race heated up. So, who is this under-the-rada...
Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, October 29, 2020, the Company will release financial results for the second quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, October 29, 2020 at 8:00 a.m. ET. Michael R. Mino...
The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients will be highlighted at T...
Let's face it, today's retail investor is bombarded with information, and parsing through what is useful and what is not can be challenging. Avoiding noise and executing under pressure are critical to investing success. I've been managing custom-built equity portfolios since 2012,...
DexCom’s (NASDAQ: DXCM ) success can be attributed to the rapid adoption by the diabetic community of its innovative continuous glucose monitoring ("CGM") system. This disposable device worn on the body continuously downloads the patient's blood sugar to a smartphone and therefore ...
Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Raymond James North American Equities Conference (virtual) on Thursday, Sep...
Abiomed, Inc . (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the 18 th Annual Morgan Stanley Global Healthcare Conference (virtual) on Tues...
Most growth investors focus on technology stocks but they should also consider the healthcare sector, where valuations are more reasonable. Veeva Systems Inc. (VEEV), ABIOMED, Inc. (ABMD), PerkinElmer, Inc. (PKI), and Charles River Laboratories International, Inc. (CRL) are four healthcare stoc...
In the days and weeks leading up to the start of the coronavirus pandemic, the S&P 500 index was hitting all-time highs. On Feb. 19 of this year, it achieved a record peak since the Great Recession of 2008, closing at 3,386.15. Then the bottom fell out. By March 23, the S&P 500 ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...